v3.26.3
Description of Business and Basis of Preparation - Additional Information (Detail)
$ / shares in Units, $ in Thousands
 9 Months Ended
Sep. 25, 2026
USD ($)
May 28, 2026
shares
Sep. 30, 2026
USD ($)
$ / shares
shares
Jun. 26, 2026
$ / shares
shares
Jun. 25, 2026
shares
May 29, 2026
shares
Dec. 31, 2025
USD ($)
$ / shares
shares
Product Information [Line Items]              
Ownership rights, description     The Company owns 100% of the intellectual property covering SCY-247, as well as additional fungerp compounds in preclinical and discovery stages of development. The FDA has granted Qualified Infectious Disease Product status, Fast Track, and Orphan Drug designations for SCY-247. In September 2026, the Company announced it had been awarded contract number 75A50126C00007 (the "BARDA Contract") by the Biomedical Advanced Research and Development Authority ("BARDA") to advance the development of SCY-247 in the treatment of invasive candidiasis and prevention of invasive fungal infections in high-risk patients. The BARDA Contract provides for potential total non-dilutive funding by BARDA of up to $213.9 million. The initial base period of the BARDA Contract commences in September 2026 and provides approximately $18.5 million to support the advancement of oral and intravenous SCY-247 into a Phase 2 study in patients with invasive candidiasis. The balance of the award is subject to BARDA exercising up to six options which could extend the term of the BARDA Contract for up to ten years.        
Owns percentage of right     100.00%        
Accumulated deficit     $ (407,504)       $ (385,144)
Cash and cash equivalents and investments     $ 63,200        
Reverse stock split conversion ratio   0.125          
Common stock, shares authorized (in shares) | shares   150,000,000 60,000,000 65,000,000 23,750,000 18,750,000 60,000,000
Common stock, shares issued (in shares) | shares   79,459,299 9,952,738     9,932,359 5,442,688
Common stock, shares outstanding (in shares) | shares   79,459,299 9,952,738     9,932,359 5,442,688
Common stock, par value (in dollars per share) | $ / shares     $ 0.001 $ 0.001     $ 0.001
BARDA Contract | BARDA              
Product Information [Line Items]              
Maximum non-dilutive funding $ 213,900            
Initial base to support advancement of oral and intravenous SCY-247 $ 18,500            
Maximum | BARDA Contract | BARDA              
Product Information [Line Items]              
Extended contract period     10 years